Tecvayli (teclistamab-cqyv) Letter of Medical Necessity
Tecvayli (teclistamab) is a BCMA-directed bispecific antibody for heavily pretreated multiple myeloma. It is billed on the medical benefit and governed by a REMS program, so PA reviewers look for precise prior-line documentation, REMS certification, and a step-up dosing plan with hospitalization. Missing any one triggers a denial.
FDA-Approved Indications
- ● relapsed or refractory multiple myeloma after at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody
Why Tecvayli Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Prior lines of therapy (PI, IMiD, anti-CD38) not documented in sufficient detail
- 2. Prescriber or facility REMS certification not documented
- 3. Step-up dosing hospitalization plan and site of care not specified
- 4. Billed under the wrong benefit (medical vs pharmacy) or missing HCPCS code
- 5. Prior BCMA-directed therapy history not addressed
What to Include in a Tecvayli Letter of Medical Necessity
List each prior line of therapy with agents, dates, best response, and progression, confirming exposure to a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody. Document REMS certification, the step-up dosing schedule and inpatient monitoring plan, prior BCMA-directed therapy if any, baseline labs and infection prophylaxis, and cite the NCCN category of evidence.
Key clinical evidence to cite:
- ✓ MajesTEC-1 Phase 1/2 trial — durable responses in triple-class-exposed relapsed/refractory multiple myeloma
- ✓ Off-the-shelf bispecific with no manufacturing wait, unlike autologous CAR-T
- ✓ REMS program with structured CRS and neurotoxicity (ICANS) monitoring
Relevant guidelines:
- 📖 NCCN Multiple Myeloma Guidelines
- 📖 IMWG Response Criteria
- 📖 ASTCT CRS and ICANS Consensus Grading
Tecvayli Prior Authorization Criteria
Standard criteria across major US payers for Tecvayli. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Prior lines of therapy (PI, IMiD, anti-CD38) not documented in sufficient detail
- → Step-up dosing hospitalization plan and site of care not specified
- → Prior BCMA-directed therapy history not addressed
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Tecvayli
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Tecvayli Prior Authorization FAQ
Why was my Tecvayli prior authorization denied?
The most common denial reasons for Tecvayli are: Prior lines of therapy (PI, IMiD, anti-CD38) not documented in sufficient detail; Prescriber or facility REMS certification not documented; Step-up dosing hospitalization plan and site of care not specified; Billed under the wrong benefit (medical vs pharmacy) or missing HCPCS code; Prior BCMA-directed therapy history not addressed.
What should a Tecvayli Letter of Medical Necessity include?
List each prior line of therapy with agents, dates, best response, and progression, confirming exposure to a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody. Document REMS certification, the step-up dosing schedule and inpatient monitoring plan, prior BCMA-directed therapy if any, baseline labs and infection prophylaxis, and cite the NCCN category of evidence.
Which payers cover Tecvayli?
Tecvayli is covered by major US payers including UnitedHealthcare, Aetna, Cigna, Anthem BCBS, Humana, Medicare Part B, though formulary tier and prior authorization criteria vary.